Decrease of functioning in remitted and non-remitted patients 16 years after a first-episode schizophrenia by Marchesi, Carlo et al.
ORIGINAL ARTICLEDecrease of Functioning in Remitted and Non-Remitted Patients
16 Years After a First-Episode SchizophreniaCarlo Marchesi, MD,* Andrea Affaticati, MD,† Alberto Monici, MD,† Chiara De Panfilis, MD,*
Paolo Ossola, MD,* Rebecca Ottoni, MD,* and Matteo Tonna, MD†Abstract: In schizophrenia, a better level of functioning has been generally
associated with symptomatic remission. However, this association has been sup-
ported by cross-sectional studies or by studies with a short follow-up period.
Forty-eight patients with schizophrenia were evaluated by the Positive and Neg-
ative Symptoms Scale and the Social and Occupational Functioning Assess-
ment Scale (SOFAS) at the first episode and after a mean period of 16 years.
At follow-up, patients were defined as remitters (R) or non-remitters (NR)
according to the Remission Schizophrenia Working Group criteria. R (n = 18;
37.5%) compared to NR showed at the first episode a lower illness severity and
a better level of functioning. A functional decline was found in both groups
at follow-up, even though NR showed a more than twofold reduction than R.
Better SOFAS scores at follow-up were predicted by baseline SOFAS score
and less severe negative symptoms at follow-up. Schizophrenia implies a func-
tional decline over time, regardless of the symptomatic remission status with
negative symptoms playing a major role.
Key Words: Schizophrenia, remission, illness severity, positive and negative
symptoms, long-term follow-up
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A mong the major psychiatric disorders, the longitudinal course andoutcome of schizophrenia have been the most extensively studied
(Hegarty et al., 1994) because its definition was formerly based, at least
in part, on its longitudinal course. Since the description of dementia
praecox (Kraepelin, 1899), schizophrenia has been conceptualized as
a chronic illness leading to mental deterioration, lack of volition, and
social incompetence (Lasser et al., 2007). However, some authors chal-
lenged this circular reasoning (because chronic course is used to deter-
mine diagnosis, schizophrenia is obviously a chronic illness) (Lieberman
et al., 2001) and suggested that outcome in schizophrenia is a com-
plex phenomenon in which the ability of the diagnosis to predict a
specific outcome has often been overstated (McGlashan, 2008). Support-
ing this criticism, many factors have been associated with poor outcome
such as poor premorbid adjustment, male gender, younger age at onset,
insidious onset, longer interval from the onset to treatment, and severity
of symptoms (Andreasen, 2006).
Concerning the premorbid level of functioning, there is general
agreement that schizophrenia is characterized by the presence of a
premorbid social deficit, i.e., “inadequate pre-psychotic adjustment
with little interest in other people or activities of life” (McGlashan,
2008). Such emergence of impaired social competence in the prodro-
mal phase of schizophrenia can impact the subsequent course of the dis-
order (Gelber et al., 2004; Hafner et al., 1992; Harrow and Jobe, 2007),
confirming earlier observations that the level of social maturity reached
before the breakdown influences the outcome of a schizophrenic epi-
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Copyright © 2015 Wolters Kluwer HRemission has long been considered largely impossible in
schizophrenia, to the extent that diagnosis and prognosis were viewed
as essentially the same (McGlashan, 2008) and a dramatic improvement
during the course of the illness was viewed as a sign of earlier misdiag-
nosis. Recently, however, the Remission in Schizophrenia Working
Group (RSWG) (Andreasen et al., 2005) posited that “symptomatic re-
mission is a definable concept and an achievable stage in the treatment
of schizophrenia” and proposed criteria for symptomatic remission to
support a positive, longer-term approach regarding outcome for pa-
tients with schizophrenia. According to these criteria, a relevant propor-
tion of patients (45% to 70%) (Lambert et al., 2010) can be defined as
remitters at some point during the course of their illness. Importantly,
maintaining low levels of psychopathologymay promote productive so-
cial and occupational pursuits in these patients (Opler et al., 2007). In
support to this view, studies assessing the relationship between remis-
sion (defined according to the RSWG criteria) and functional outcome
found significantly better levels of functioning in remitted versus non-
remitted patients, even though remitted patients showed areas with an
inadequate level of functioning (Addington and Addington, 2008;
Bobes et al., 2009; Bodén et al., 2009; Karow et al., 2012; Oorschot
et al., 2012). These studies confirmed the results of previous investiga-
tions using different criteria than those proposed by RSWG (Lasser
et al., 2007; Lambert et al., 2008; Lang et al., 2013).
However, studies that applied the RSWG criteria varied sub-
stantially in terms of the evaluation time because remission and func-
tioning were assessed cross-sectionally (Oorschot et al., 2012; Helldin
et al., 2007), or 2 months after the baseline evaluation (Schennach-
Wolff et al., 2009), 1 to 3 years since the first assessment (Bodén et al.,
2009; Addington and Addington, 2009; Chang et al., 2013), or after
longer time periods (5–7 years) (Bobes et al., 2009; Ceskova et al.,
2011; Kurihara et al., 2011). To our knowledge, no study assessed
the association between RSWG-defined remission and level of func-
tioning in patients with schizophrenia after more than 7 years from their
first episode of illness. Further, no study investigated if the level of func-
tioning at first admission declines in patients who achieve remission in
the course of a long-term follow-up and long duration of illness.
Therefore, the present prospective study assessed patients with
schizophrenia both at the time of their first episode and after a mean
period of 16 years to examine whether (1) a better level of functioning
was associated with the achievement of remission (RSWG criteria)
compared to non-remitted patients, (2) remitted patients were charac-
terized by higher levels of functioning at first admission than non-
remitters, and (3) the level of functioning at onset deteriorated even
in remitted patients, according to a Kraepelinian conceptualization of
schizophrenia.METHODS
Sample
The study participants were recruited from patients who were
consecutively admitted to the Psychiatry Clinic of the University of
Parma, from January 1995 to December 1999, because of a first psy-
chotic episode. To the Psychiatry Clinic were referred patients fromrvous and Mental Disease • Volume 203, Number 6, June 2015
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The Journal of Nervous and Mental Disease • Volume 203, Number 6, June 2015 Functioning and Symptom Remissiona population of about 400,000 people. This study is part of a more
extensive evaluation of long-term outcome in patients with a first psy-
chotic episode.
Patients were included in the study if (1) they were aged over
17 years; (2) they were admitted for the first time in a psychiatric unit
for a first psychotic episode; (3) they were discharged with a diagnosis
of Schizophrenia, according to the DSM-IV; and (4) they gave awritten
informed consent.
Patients were excluded from the study if (1) they were affected
by drug abuse or drug dependence, delirium, mental retardation, or
organic mental disorders; (2) they were previously treated with antipsy-
chotic medications; and (3) they did not assure treatment adherence
or they discontinued the treatment program after discharge from hos-
pital for more than two consecutive visits (see follow-up evaluation).
Because the aim of the study was the long-term outcome of patients
properly treated for schizophrenia, drug abuse or dependence and non-
adherence to treatment were considered exclusion criteria to avoid their
confounding effects on outcome.
The participants gave written consent after complete description
of the study.
Assessment
The period of enrollment lasted from January 1995 to December
1999. Patients were evaluated a first time during the index hospitaliza-
tion and a second time in the year 2010.
Baseline Assessment
The baseline evaluation was carried out within the first week of
hospitalization. Sociodemographic variables recorded at baseline were
age, gender, years of education, marital and employment status, hous-
ing situation, age at onset of schizophrenia, and the time passed from
the onset of first psychotic symptoms or behavioral changes and hospi-
talization, where patients received antipsychotic treatment for the first
time (see exclusion criteria).
To formulate the diagnosis, we used the information obtained
from the Structured Clinical Interview for Axis I DSM-IV disorders, car-
ried out by trained psychiatrists, together with the information collected
from family members, medical records, and primary treating physicians.
The severity of symptoms was measured with the Positive and
Negative Symptoms Scale (PANSS) (Kay et al., 1987). We used five
PANSS scores: positive, negative, general psychopathology, cognitive,
and total scores. The cognitive PANSS score was calculated, accord-
ing to Llorca et al. (2012), by adding the score of the items disorienta-
tion (G10), attention deficit (G11), and difficulty in abstract thinking
(N5). Consequently, the negative and general psychopathological scores
were calculated without the items included in the cognitive score.
Further, according to the PANSS criteria, patients were defined
as affected by positive schizophrenia (if they reported a score equal
or higher than four in at least three items of positive scale and in less
than three items of negative scale), negative schizophrenia (if they
reported a score equal or higher than four in at least three items of
negative scale and in less than three items of positive scale), or mixed
schizophrenia (if they reported a score equal or higher than four in at
least three items of positive and negative scales).
The level of functioning was evaluated using the Social and
Occupational Functioning Assessment Scale (SOFAS) (APA, 2000).
For the attribution of the SOFAS score, we evaluated the habitual way
of daily living of each patient in the year before the onset of psychotic
symptoms as specified in the instruction for the use of the scale “The
SOFAS may also be useful to evaluate functioning for the past year
(i.e., the highest level of functioning for at least a few months during
the past year)” (page 760) (APA, 2000).
The period of time from the onset of first psychotic symptoms
to the hospitalization where patients received treatment for the first
time was also calculated.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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After discharged from hospital, patients accessed continuous
and reasonably comprehensive public mental health services (Amaddeo
et al., 2012), where they attended nearly monthly visits.
During each visit, their psychopathological condition, treatment
adherence, medications prescription, and use of illicit drugs were clin-
ically evaluated. The number of psychotic episodes and the number
and time of hospitalization were also computed. A psychotic episode
(relapse) was defined on the clinical judgment as the reappearance of
delusions, hallucinations, and/or behavioral disorganization.
Patients were re-examined in 2010 by a psychiatrist blind to the
baseline evaluation. The follow-up assessment consisted in the admin-
istration of SCID-IV, PANSS, and SOFAS. After 8 months, the patients
were re-evaluated with the PANSS to verify whether the time criterion
of 6 months requested for remission, as suggested by RSWG, was sat-
isfied. Patients were defined in remission (R) or in non-remission (NR),
according to both severity and time criteria proposed by the RSWG.
Treatment
All patients were treated with antipsychotic medications. The
choice of medication was made on the basis of clinical evaluation and
according to the preference of patients and their relatives.
To maximize the treatment adherence, a medication control by
relatives was recommended and the count of pills was performed at
any time the medication was prescribed. In patients who did not assure
a treatment adherence, the use of a long-acting medication was pro-
posed. Patients were considered non-adherent if they reported stopping
their antipsychotic for 1 week or more.
Patients also received non-pharmacological treatment such as
psycho-education program (together with their families) and social
skills and vocational training. In particular, a family psycho-education
program was administered only at the beginning of the follow-up
period. The program consisted of weekly sessions of 90 minutes for
6 months according to Falloon model (Falloon and Fadden, 1993).
Data Analysis
Before the start-up of the study and the follow-up evaluations,
an inter-rater reliability was calculated for the diagnosis of schizo-
phrenia (baseline: k = 0.92; follow-up: k = 0.95) for the PANSS total
score (baseline: k = 0.82; follow-up: k = 0.80) and for the SOFAS score
(baseline: k = 0.79; follow-up: k = 0.81).
The clinical and sociodemographic features were compared in
R and in NR using the two-tailed Student’s t test for continuous vari-
ables and the χ2 test for the categorical variables.
The change of symptom severity and SOFAS scores between
the baseline and follow-up assessments was evaluated in R and in NR
using the two-tailed Student’s t test for paired data.
Finally, a multiple regression analysis, stepwise method was
used to evaluate the baseline predictors of level of functioning at
follow-up. In this analysis, SOFAS score at follow-up was entered as
the dependent variable, whereas variables which at baseline showed
significant differences between R and NR (baseline SOFAS score,
PANSS type, PANSS total score at baseline, number of psychotic epi-
sodes and time of hospitalization during follow-up, state of remission,
PANSS scores for positive, negative, cognitive, and general psychopa-
thology symptoms at follow-up) (Table 1) were entered as independent
variables.
All statistical analyses were performed with SPSS for Windows
(version 20; SPSS Inc., Chicago, IL, USA).RESULTS
During the period of enrollment, 70 patients were consecutively
admitted to the Psychiatric Clinic of the University of Parma for a firstwww.jonmd.com 407
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TABLE 1. Sociodemographic and Clinical Features of Schizophrenic Patients With or Without Remission
Remission
Yes n = 18 No n = 30 Total n = 48
n % n % n % χ2 p
Gender 0.28 0.59
Male 10 55.5 19 63.3 29 60.4
Marital status 3.65 0.16
Never married 13 72.2 22 73.3 35 72.9
Married 5 21.8 4 13.3 9 18.8
Divorced/widowed 0 0.0 4 13.3 4 8.3
Working status 6.46 0.01
Never occupied 4 22.2 18 60.0 22 45.8
Occupied 14 77.8 12 40.0 26 54.2
Living status 0.59 0.44
Living alone 8 44.4 10 33.3 18 37.4
Living with someone 10 55.6 20 66.7 30 62.5
Schizophrenia type (DSM-IV) 3.47 0.24
Paranoid 16 88.9 23 76.7 38 81.3
Disorganized 0 0.0 5 16.7 5 10.4
Undifferentiated 2 11.1 2 6.7 4 8.3
Schizophrenia type (PANSS scores, restrictive criteria) 11.3 0.002
Positive 15 83.3 10 33.3 25 52.1
Negative 0 0.0 1 3.3 1 2.1
Mixed 3 16.7 19 63.3 22 45.8
Mean ± SD Mean ± SD Mean ± SD t p
Age, years 41.0 ± 11.3 46.5 ± 14.1 43.2 ± 11.1 1.32 0.17
Age at onset, years 22.2 ± 3.8 21.6 ± 5.8 21.8 ± 5.1 0.38 0.70
DUP, weeks 18.0 ± 4.5 19.7 ± 4.4 19.0 ± 4.5 1.21 0.20
Follow-up duration, years 16.3 ± 5.1 16.0 ± 4.8 16.2 ± 4.9 0.18 0.85
No. psychotic episodes 2.2 ± 0.6 3.6 ± 1.0 6.3 ± 6.4 4.7 <0.001
Hospitalization number 2.6 ± 0.7 3.8 ± 0.9 6.8 ± 7.1 3.9 <0.001
Hospitalization, months 5.3 ± 0.6 7.5 ± 1.9 6.6 ± 1.8 4.6 <0.001
Marchesi et al. The Journal of Nervous and Mental Disease • Volume 203, Number 6, June 2015psychotic episode and discharged with a diagnosis of schizophrenia.
Among them, 56 accepted to participate in the study.
In 2010, at the time of the follow-up assessment, six patients
had moved outside the study area and two patients refused further psy-
chiatric evaluation for the present study. Therefore, only 48 patients
were re-evaluated at follow-up.
The SCID-IV re-administration confirmed the stability of schizo-
phrenia diagnosis in all 48 patients, and 18 of them (37.5%) satis-
fied remission RSWG criteria (R), whereas the remaining 30 patients
(62.5%) did not (NR). None of them was using illicit drugs.Sociodemographic Characteristics
At first episode, only working status differed between R and
NR patients: R patients were more likely to be employed than NR
patients (χ2 = 6.4; p = 0.01) (Table 1). The duration of untreated psy-
chosis was short in our sample (Table 1), and no difference was found
between R and NR patients.
At follow-up, duration of illness was similar in R and in NR pa-
tients, whereas the number of psychotic relapses and the number and
length of hospitalization during the follow-up period were lower in R
than in NR (Table 1).408 www.jonmd.com
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A lesser symptom severity at baseline was found in R than in
NR patients: all PANSS dimension scores (positive, negative, cognitive,
general psychopathology, and total scores) were lower in R than in NR
patients (Table 2).
At follow-up, symptom severity was reduced in both groups
of patients as compared to baseline: the decrease reached a statistical
significance for PANSS positive, cognitive, general psychopathology,
and total scores, but not for negative score, in both R and NR patients
(Table 2).Treatment
Forty-one patients (85.5%) were treated with oral antipsychotics
and the remaining seven patients (14.5%) received a long-acting anti-
psychotic injection (LAI). A second-generation antipsychotic (SGA)
was administered in 34 patients (70.8%) and a first-generation anti-
psychotic (FGA) was used in 14 patients (29.2%). Seven patients
switched from an oral FGA to a LAI and 11 patients from a FGA to a
SGA. No patient was treated with antipsychotic combination or with
electroconvulsive therapy.© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 2. Symptom Severity (PANSS Scores) and Social and Occupational Functioning Assessment Scale Score in Remitted (R) and in
Non-Remitted (NR) Patients
Remission t Test for Paired Sample
Yes No Yes vs. No Baseline vs. Follow-Up
n = 18 n = 30 Baseline Follow-Up Yes No
PANSS Symptoms Baseline Follow-Up Baseline Follow-Up t t t t
Positive 24.8 ± 3.7 11.0 ± 2.7 28.1 ± 4.0 17.2 ± 5.8 2.7** 4.2** 13.9** 11.5**
Negative 15.6 ± 2.6 14.3 ± 2.6 22.0 ± 3.7 21.1 ± 4.1 6.3** 6.2** 1.8 1.4
General 42.1 ± 3.6 29.4 ± 5.2 50.4 ± 4.9 37.7 ± 6.3 6.6** 4.7** 8.9** 12.7**
Cognitive 6.1 ± 2.1 5.2 ± 1.5 8.6 ± 1.9 6.9 ± 2.4 4.3** 2.5* 2.0 4.7**
Total score 88.8 ± 6.2 60.7 ± 10.5 109 ± 10.0 83.0 ± 14.2 7.7** 4.6** 10.5** 12.2**
SOFAS score 67.7 ± 7.3 62.2 ± 7.3 58.0 ± 8.7 45.3 ± 10.6 6.1** 5.9** 10.0** 8.4**
PANSSNegative: all negative symptoms except difficulty in abstract thinking score. PANSSGeneral: all general psychopathological symptoms except disorientation
and poor attention. PANSS Cognitive: disorientation, poor attention and difficulty in abstract thinking.
*p < 0.05; **p < 0.001.
The Journal of Nervous and Mental Disease • Volume 203, Number 6, June 2015 Functioning and Symptom RemissionLevel of Functioning
At baseline, the SOFAS score was higher in R than in NR pa-
tients (Table 2). At follow-up, a significant decrease in SOFAS score
was observed in both R and NR patients (Table 2), but this decrease
was smaller in R (5.5 ± 2.3) than in NR patients (12.6 ± 8.1) (t = 3.4;
df = 46; p = 0.001) (Fig. 1).
In the multiple regression analysis, the SOFAS score at base-
line and the PANSS negative score at follow-up predicted the SOFAS
score at follow-up, whereas no effect was observed for PANSS type,
baseline PANSS total score, number of psychotic episodes and time
of hospitalization during follow-up, PANSS positive, cognitive, and
psychopathological general scores at follow-up, and the remission sta-
tus (Table 3). This regression model explained 77% of variance (R2)
of the SOFAS score at follow-up.
DISCUSSION
The present study aimed at evaluating the long-term course and
the potential correlates of functional impairment in a sample of 48 reli-
ably diagnosed patients with schizophrenia. The level of psychosocialFIGURE 1. SOFAS score in remitted and in non-remitted schizophrenic
patients in the year before the first episode and at follow-up.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hfunctioning as well as the severity of symptoms was assessed both at
the first episode and after a mean period of 16 years of illness.
At follow-up, 18 patients (37.5%) (R) satisfied the remis-
sion criteria (both severity and time criteria) proposed by the RSWG
(Andreasen et al., 2005), whereas the remaining 30 patients did not
reach remission (NR).
Remitted Versus Non-Remitted Patients at First
Episode and Follow-Up
Remitters and non-remitters showed clinical differences at their
first episode of illness: R patients had a lower severity of symptoms
and a better level of functioning in the year before the first admission
than NR. After 16 years of illness, an improvement in PANSS positive,
cognitive, and general psychopathological symptomswas found in both
R and NR, whereas no change in severity of negative symptoms was
observed in the two groups. In contrast, a decrease of functioning was
observed regardless of the achievement of the symptomatic remission,
although a more than twofold reduction of SOFAS scores was found
in NR than in R.
Therefore, our findings suggest that remission of symptoms,
although associated with a better functioning, do not completely pre-
vent the worsening of social abilities, but may mitigate the functional
decline if compared to non-remission.
On the one hand, these findings are in keeping with several pre-
vious studies (Addington and Addington, 2008; Bobes et al., 2009;TABLE 3. Baseline Predictors of the SOFAS Score at Follow-Up
(Stepwise Multiple Regression Analysis)
SOFAS Score at Follow-Up b t p R2
Step 1 0.65
SOFAS score at baseline 0.80 9.2 <0.001
Step 2 0.77
SOFAS score at baseline 0.49 5.2 <0.001
PANSS Negative symptoms score
at follow-up
−0.47 −4.9 <0.001
In the multiple regression analysis, PANSS type, baseline PANSS total score,
baseline SOFAS score, follow-up PANSS positive, negative, cognitive, and gen-
eral psychopathological symptoms scores, number of psychotic episodes, time
of hospitalization, and remission status (0 = no; 1 = yes) entered as independent
variables.
www.jonmd.com 409
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demonstrated that remission of symptoms was associated with a better
level of functioning. On the other hand, they suggest that the decline
in psychosocial functioning seems to be inherently associated with
the course of the illness because a decrease in social abilities was also
observed in R patients. Consistently, the regression analysis demon-
strated that symptomatic remission did not predict a better functional
outcome at follow-up.
Symptom Severity and Social Functioning
A possible interpretation of these results is that low-mild symp-
toms, which do not significantly interfere with behavior, may let the R
individual to develop coping mechanisms and to better respond to psy-
chosocial therapies and rehabilitation interventions. In contrast, more
severe symptoms may negatively influence the levels of functioning,
so as to explain a greater deterioration in social functions in NR than
in R patients. Nevertheless, overall social functioning appears toworsen
over time in both R and NR patients. This means that a greater symp-
tom severity cannot justify alone the poorer functional outcome in
NR. In fact, NR showed a greater deficit of functioning already at the
onset of the illness and a greater functional impairment over the course
of follow-up in opposition to the improvement of most of their symp-
toms (i.e., positive, general psychopathology, and cognitive).
Interestingly, an inverse relationship between negative symp-
toms severity and functional outcome was observed because a higher
PANSS negative score at follow-up was related to a lower SOFAS score
at the end of the study, thus confirming the results of previous long-
term studies (Bobes et al., 2009; Ceskova et al., 2011; White et al.,
2009). In the present study, the severity of negative symptoms appeared
stable over time, which seems in contrast with the decline in function-
ing over time. This might confirm that functional impairment is only
partly dependent from symptom severity and that other mechanisms,
i.e., cognitive dysfunctions and premorbid functioning (Lieberman
et al., 2001; Bowie et al., 2008; Walker, 1994), might be involved in
the decrease of social functioning. Nevertheless, it cannot be excluded
that negative symptoms might exert a continuous and cumulative effect
on functioning, which was maintained independently from an increase
in their severity.
Premorbid Functioning and Outcome
As a further suggestion that other factors besides symptom di-
mensions may be involved in the deterioration of levels of functionality,
we found that the poor SOFAS score at baselinewas the major predictor
of SOFAS score at follow-up. Thus, our findings confirm the long-
standing observation that social abnormalities are already present at
the onset of illness and that poorer adjustment at the onset is associated
with a decline of social functioning (Lieberman et al., 2001; Chang et al.,
2013; Ayesa-Arriola et al., 2013). A poor premorbid adjustment has been
postulated to be indicative of a more deteriorating form of illness, and a
poor adjustment in the year before the first admission (a SOFAS score
lower than 70) was observed in 91.7% of our patients. This finding
may explain why in the current study a worsening of functioning was
found in all of our patients regardless of their clinical improvement.
The relationship between first-episode adjustment and negative
symptoms is complex and difficult to disentangle. Interestingly, previ-
ous studies suggested that premorbid maladjustment, and particularly
impairment in social functioning, may represent a precursor of negative
symptoms (Chang et al., 2013). Therefore, we may hypothesize that in
our patients a poor social functioning at first admission may facilitate
the onset of negative symptoms, which in turn contributes to the further
deterioration of social functions.
Limitations
The present study has the following limitations.410 www.jonmd.com
Copyright © 2015 Wolters Kluwer HFirst, symptom severity was evaluated with PANSS only at onset
and after a mean period of 16 years of illness, raising the question of
how representative the last 6 months of illness are for the total duration
of illness. However, it is well known that the remission status could not
be a stable condition, and even though in the present study patients in
remission had relapses, they showed a less number of relapses than in
non-remitters, suggesting a more favorable course of illness in remitters
than in non-remitters.
Second, we evaluated social functioning only with a unidimen-
sional instrument (SOFAS) instead of using multivariate measures.
Therefore, different areas of social and daily functioning could not be
specifically assessed to verify which area of long-term social functions
was impaired in our patients.
Third, we evaluated cognitive symptoms only by the means
of the PANSS items “disorientation, attention deficit and difficulty in
abstract thinking”. Therefore, a more comprehensive cognitive evalua-
tion is warranted before concluding that cognitive deficit does not im-
pact on long-term functioning, as we found in the present study.
However, recent studies found that neurocognition deficits did not pre-
dict long-term functional outcome (Ayesa-Arriola et al., 2013).
Finally, the current study includes patients who were treated a
short time after the onset of psychotic symptoms, who were strictly
treatment adherent and substance use free. Thus, the results of the study
are not applicable to overall schizophrenia patients.
CONCLUSIONS
In conclusion, the present study indicates that, first, symptomatic
remission is not necessarily associated with functional improvement
because symptoms and social functioning do not follow a parallel
course; second, the level of functionality in the year before the first
admission is the major predictor of the functional outcome after many
years of illness, explaining most (65%) of the variance of SOFAS score
at the end of the study; third, negative symptoms, associated with poor
social functioning in the year before the first admission, exert a cumu-
lative effect on the decline of social functions.
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